Payment will not be made for any use of these drugs outside of the criteria without prior authorization. The member may not be billed unless the member explicitly agrees in writing to be responsible for the charges in accordance with the contract/provider manual. Prior authorization will only be given if the provider demonstrates the intended use meets Medicare coverage guidelines.

**Coverage Guidelines:**

**Off Label:**
1. Neovascular (wet) age-related macular degeneration
2. Diabetic macular edema
3. Central retinal vein occlusion
4. Venous tributary (branch) occlusion
5. Histoplasmosis retinitis
6. Proliferative diabetic retinopathy
7. Severe nonproliferative diabetic retinopathy
8. Retinal neovascularization
9. Cystoid macular degeneration
10. Angioid streaks of choroid
11. Glaucoma associated with vascular disorders

**Coding Information:**

<table>
<thead>
<tr>
<th>HCPCS Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9035 INJECTION, BEVACIZUMAB, 10 MG</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-9 Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>115.02 INFECTION BY HISTOPLASMA CAPSULATUM-RETINITIS</td>
<td></td>
</tr>
<tr>
<td>115.12 INFECTION BY HISTOPLASMA DUBOISII-RETINITIS</td>
<td></td>
</tr>
<tr>
<td>115.92 OCULAR HISTOPLASMOSIS</td>
<td></td>
</tr>
<tr>
<td>362.02 PROLIFERATIVE DIABETIC RETINOPATHY</td>
<td></td>
</tr>
</tbody>
</table>
Background:
Bevacizumab is a recombinant human monoclonal IgG1 antibody that reduces angiogenesis in neoplastic and other cells.

Definitions:

HCPCS Code—Healthcare Common Procedure Coding System - A system of letter and number codes assigned to procedures, medications, supplies and equipment used for pricing and billing.

ICD-9 Code—International Classification of Disease, 9th edition. A standardized classification of disease, injuries, and causes of death, by etiology and anatomic localization and codified into a 6-digit number, which allows clinicians, statisticians, politicians, health planners and others to speak a common language, both US and internationally.
FDA Black Box Warning:

**WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE.**

**Gastrointestinal Perforations**
The incidence of gastrointestinal perforation, some fatal, in Avastin-treated patients ranges from 0.3 to 2.4%. Discontinue Avastin in patients with gastrointestinal perforation.

**Surgery and Wound Healing Complications**
The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin-treated patients. Discontinue Avastin in patients with wound dehiscence. The appropriate interval between termination of Avastin and subsequent elective surgery required to reduce the risks of impaired wound healing/wound dehiscence has not been determined. Discontinue at least 28 days prior to elective surgery. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed.

**Hemorrhage**
Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, central nervous system (CNS) hemorrhage, epistaxis, and vaginal bleeding occurred up to five-fold more frequently in patients receiving Avastin. Do not administer Avastin to patients with serious hemorrhage or recent hemoptysis.

References:

3. Local Coverage Determination (LCD) for Drugs and Biologics: Antiangiogenic Therapy for Ophthalmic Conditions (L30555) (Revision 3). Available at: http://www.cms.gov/medicare-coverage-database/details/lcd-.
This policy has been developed for informational purposes only and constitutes neither offers of coverage nor operates as a substitute for professional healthcare advice. This document contains confidential and proprietary information of VIVA Health which may not be reproduced, distributed or printed without prior permission from VIVA Health. In addition, it contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with VIVA Health. VIVA Health makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability of the information contained herein. VIVA Health assumes no responsibility for errors or omissions contained herein or any subsequent reliance upon said information.